363 related articles for article (PubMed ID: 18047178)
1. In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.
Asyarie S; Rachmawati H
PDA J Pharm Sci Technol; 2007; 61(5):400-10. PubMed ID: 18047178
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions.
Patil MP; Gaikwad NJ
Acta Pharm; 2009 Mar; 59(1):57-65. PubMed ID: 19304558
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.
Biswal S; Sahoo J; Murthy PN; Giradkar RP; Avari JG
AAPS PharmSciTech; 2008; 9(2):563-70. PubMed ID: 18459056
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation and in vivo performance of lyophilized gliclazide.
Mansour HF; Aly UF
Drug Dev Ind Pharm; 2015 Apr; 41(4):650-7. PubMed ID: 24568609
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion.
Khattab IS; Nada A; Zaghloul AA
Drug Dev Ind Pharm; 2010 Aug; 36(8):893-902. PubMed ID: 20196643
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.
Yin LF; Huang SJ; Zhu CL; Zhang SH; Zhang Q; Chen XJ; Liu QW
Drug Dev Ind Pharm; 2012 Nov; 38(11):1371-80. PubMed ID: 22296267
[TBL] [Abstract][Full Text] [Related]
7. Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide.
El-Maghraby GM; Alomrani AH
Pak J Pharm Sci; 2011 Oct; 24(4):459-68. PubMed ID: 21959805
[TBL] [Abstract][Full Text] [Related]
8. A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.
Yang Y; Zhao Z; Wang Y; Yang L; Liu D; Yang X; Pan W
Int J Pharm; 2016 Jun; 506(1-2):340-50. PubMed ID: 27132166
[TBL] [Abstract][Full Text] [Related]
9. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery.
Kumar BS; Saraswathi R; Kumar KV; Jha SK; Venkates DP; Dhanaraj SA
Drug Deliv; 2014 May; 21(3):173-84. PubMed ID: 24102185
[TBL] [Abstract][Full Text] [Related]
11. Preparation of osthole-polymer solid dispersions by hot-melt extrusion for dissolution and bioavailability enhancement.
Yun F; Kang A; Shan J; Zhao X; Bi X; Li J; Di L
Int J Pharm; 2014 Apr; 465(1-2):436-43. PubMed ID: 24576810
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
[TBL] [Abstract][Full Text] [Related]
13. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier.
Khan AW; Kotta S; Ansari SH; Sharma RK; Ali J
Drug Dev Ind Pharm; 2015 May; 41(5):772-9. PubMed ID: 24669978
[TBL] [Abstract][Full Text] [Related]
14. Development of prednisone:polyethylene glycol 6000 fast-release tablets from solid dispersions: solid-state characterization, dissolution behavior, and formulation parameters.
Leonardi D; Barrera MG; Lamas MC; Salomón CJ
AAPS PharmSciTech; 2007 Dec; 8(4):E108. PubMed ID: 18181529
[TBL] [Abstract][Full Text] [Related]
15. Preparation, characterization and tableting of cilnidipine solid dispersions.
Hu L; Song W; Niu F; Jiao K; Jia Z
Pak J Pharm Sci; 2013 May; 26(3):629-36. PubMed ID: 23625441
[TBL] [Abstract][Full Text] [Related]
16. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
Hussain T; Saeed T; Mumtaz AM; Javaid Z; Abbas K; Awais A; Idrees HA
Acta Pol Pharm; 2013; 70(4):749-57. PubMed ID: 23923399
[TBL] [Abstract][Full Text] [Related]
17. Multicomponent crystals of gliclazide and tromethamine: preparation, physico-chemical, and pharmaceutical characterization
Bruni G; Berbenni V; Maggi L; Mustarelli P; Friuli V; Ferrara C; Pardi F; Castagna F; Girella A; Milanese C; Marini A
Drug Dev Ind Pharm; 2018 Feb; 44(2):243-250. PubMed ID: 28956461
[TBL] [Abstract][Full Text] [Related]
18. Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
Al-Kassas RS; Al-Gohary OM; Al-Faadhel MM
Int J Pharm; 2007 Aug; 341(1-2):230-7. PubMed ID: 17507189
[TBL] [Abstract][Full Text] [Related]
19. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Ha ES; Kim JS; Baek IH; Yoo JW; Jung Y; Moon HR; Kim MS
Drug Des Devel Ther; 2015; 9():4269-77. PubMed ID: 26345723
[TBL] [Abstract][Full Text] [Related]
20. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide.
Hong SS; Lee SH; Lee YJ; Chung SJ; Lee MH; Shim CK
J Control Release; 1998 Feb; 51(2-3):185-92. PubMed ID: 9685916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
